MedTrace Logo

Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome

NCT07201012 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-11-17

No results posted yet for this study

Summary

The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.

Conditions

  • Basal Cell Carcinoma of Skin, Site Unspecified
  • Epidermoid Carcinoma
  • Lynch Syndrome
  • Muir-Torre Syndrome

Interventions

DIAGNOSTIC_TEST

Sampling of suspected skin lesions (in accordance with good care practices).

Sampling of suspected skin lesions (in accordance with good care practices) and swabbing of skin microbiota.

GENETIC

Constitution of a biobank

Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Pierre STOEBNER, Prof. · Nîmes University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-11-30
Completion
2027-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07201012 on ClinicalTrials.gov